Published in Nat Rev Gastroenterol Hepatol on September 25, 2012
Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. Nat Med (2013) 2.94
Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. J Allergy Clin Immunol (2014) 1.22
Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis. Gastroenterol Clin North Am (2014) 1.19
A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut (2015) 1.01
Smad3-deficient mice have reduced esophageal fibrosis and angiogenesis in a model of egg-induced eosinophilic esophagitis. J Pediatr Gastroenterol Nutr (2014) 0.90
A pilot study of omalizumab in eosinophilic esophagitis. PLoS One (2015) 0.85
Elimination diets in the management of eosinophilic esophagitis. J Asthma Allergy (2014) 0.78
Eosinophilic esophagitis: published evidences for disease subtypes, indications for patient subpopulations, and how to translate patient observations to murine experimental models. World Allergy Organ J (2016) 0.76
Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet (2006) 9.99
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology (2007) 9.05
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet (2009) 6.83
Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest (2006) 5.48
Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology (2003) 5.36
Eosinophilic esophagitis. N Engl J Med (2004) 4.43
Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology (1995) 4.24
Esophageal dilation in eosinophilic esophagitis: safety and predictors of clinical response and complications. Gastrointest Endosc (2010) 3.74
A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology (2006) 3.68
Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc (2006) 3.65
Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann Allergy Asthma Immunol (2005) 3.53
Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol (2012) 3.45
Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol (2010) 3.43
Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol (2005) 3.34
Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology (2012) 3.29
Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci (1993) 3.18
Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol (2003) 3.05
Esophageal remodeling in pediatric eosinophilic esophagitis. J Allergy Clin Immunol (2007) 2.95
Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr (1998) 2.87
Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol (2006) 2.78
Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology (2010) 2.76
Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med (1988) 2.71
Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol (2011) 2.70
Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut (2003) 2.64
Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol (2001) 2.62
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med (1996) 2.55
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut (2010) 2.47
Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet (2010) 2.47
The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol (2002) 2.43
14 years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr (2009) 2.36
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology (2010) 2.29
Subepithelial collagen deposition, profibrogenic cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult eosinophilic esophagitis: a prospective study. J Allergy Clin Immunol (2011) 2.20
Primary eosinophilic disorders of the gastrointestinal tract. Gut (2008) 2.20
Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol (2008) 2.19
Clinical, pathologic, and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases. Clin Gastroenterol Hepatol (2008) 2.12
Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County, Switzerland. J Allergy Clin Immunol (2011) 2.07
Eosinophilic esophagitis in a patient with vigorous achalasia. Gastroenterology (1978) 2.06
Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr (1998) 2.05
Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest (1999) 2.05
Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982-1999. J Allergy Clin Immunol (2010) 2.00
Identification of specific foods responsible for inflammation in children with eosinophilic esophagitis successfully treated with empiric elimination diet. J Pediatr Gastroenterol Nutr (2011) 1.93
Eosinophilic esophagitis: asthma of the esophagus? Clin Gastroenterol Hepatol (2004) 1.92
Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci (2011) 1.90
Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol (2010) 1.85
Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol (2011) 1.82
A case-control study of sociodemographic and geographic characteristics of 335 children with eosinophilic esophagitis. Clin Gastroenterol Hepatol (2008) 1.79
Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology (2007) 1.71
An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology (2011) 1.67
[Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings]. Schweiz Med Wochenschr (1994) 1.66
Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology (2012) 1.65
Eosinophilic esophagitis: analysis of food impaction and perforation in 251 adolescent and adult patients. Clin Gastroenterol Hepatol (2008) 1.65
Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy (2009) 1.64
Clinical and endoscopic features of eosinophilic esophagitis in adults. Gastrointest Endosc (2003) 1.61
Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol (2009) 1.56
Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis. J Pediatr Gastroenterol Nutr (2006) 1.56
Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov (2007) 1.52
Pathogenesis and clinical features of eosinophilic esophagitis. J Allergy Clin Immunol (2001) 1.50
Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment. J Allergy Clin Immunol (2012) 1.50
Ringed esophagus: an association with esophagitis. Am J Gastroenterol (1992) 1.47
Fragility of the esophageal mucosa: a pathognomonic endoscopic sign of primary eosinophilic esophagitis? Gastrointest Endosc (2003) 1.46
Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med (1997) 1.43
A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol (1999) 1.36
Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J Pediatr Gastroenterol Nutr (2009) 1.35
Endoscopic, bioptic, and manometric findings in eosinophilic esophagitis before and after steroid therapy: a case series. Endoscopy (2007) 1.27
Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci (2009) 1.26
Long-term outcomes in pediatric-onset esophageal eosinophilia. J Allergy Clin Immunol (2011) 1.20
Successful treatment of eosinophilic esophagitis with ciclesonide. J Allergy Clin Immunol (2012) 1.16
The role of adhesion molecules in human eosinophil and basophil recruitment. J Allergy Clin Immunol (1994) 1.12
Gastrointestinal eosinophils in health, disease and functional disorders. Nat Rev Gastroenterol Hepatol (2010) 1.06
Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol (2007) 1.04
Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol (2008) 1.01
Esophageal strictures in adult eosinophilic esophagitis: dilation is an effective and safe alternative after failure of topical corticosteroids. Endoscopy (2008) 1.00
Fluticasone and food allergen elimination reverse sub-epithelial fibrosis in children with eosinophilic esophagitis. Dig Dis Sci (2010) 1.00
A systematic review of the risk of perforation during esophageal dilation for patients with eosinophilic esophagitis. Dig Dis Sci (2010) 0.99
Acid hypersensitivity in patients with eosinophilic oesophagitis. Scand J Gastroenterol (2010) 0.98
Gastrointestinal eosinophils in health and disease. Adv Immunol (2001) 0.97
Symptomatic mid-esophageal webs. JAMA (1966) 0.90
Severe dysphagia in children with eosinophilic esophagitis and esophageal stricture: an indication for balloon dilation? J Pediatr Gastroenterol Nutr (2010) 0.89
Corrugated ringed esophagus. Am J Gastroenterol (1993) 0.79
Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County, Switzerland. J Allergy Clin Immunol (2011) 2.07
Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol (2010) 1.69
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.41
Diagnosis and management of the symptomatic duodenal diverticulum: a case series and a short review of the literature. J Gastrointest Surg (2008) 1.29
Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis (2011) 1.04
Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol (2007) 1.04
The role of psychological stress in inflammatory bowel disease: quality assessment of methods of 18 prospective studies and suggestions for future research. Digestion (2009) 1.03
Galectin-3 modulates T cell activity and is reduced in the inflamed intestinal epithelium in IBD. Inflamm Bowel Dis (2006) 0.96
First-line therapies in inflammatory bowel disease. Digestion (2012) 0.91
Placebo and other interventions in asthma. N Engl J Med (2011) 0.89
Mood and nonmood components of perceived stress and exacerbation of Crohn's disease. Inflamm Bowel Dis (2011) 0.87
Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J Crohns Colitis (2010) 0.86
Therapy of steroid-resistant inflammatory bowel disease. Digestion (2012) 0.84
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis (2015) 0.84
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis (2010) 0.81
Variant alleles of the mannose binding lectin 2 gene (MBL2) confer heterozygote advantage within Crohn's families. Scand J Gastroenterol (2010) 0.80
Association of deficiency for mannan-binding lectin with anti-mannan antibodies in Crohn's disease: a family study. Inflamm Bowel Dis (2007) 0.79
Anti-Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn's patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans. Inflamm Bowel Dis (2007) 0.79
Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. Inflamm Bowel Dis (2015) 0.78
Increased titers of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients with reduced H-ficolin levels but normal MASP-2 activity. J Crohns Colitis (2012) 0.77
A shift from oral to intravenous iron supplementation therapy is observed over time in a large swiss cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.77
Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease. Inflamm Bowel Dis (2016) 0.76
Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. Eur J Gastroenterol Hepatol (2017) 0.76
Partial overlap of anti-mycobacterial, and anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease. World J Gastroenterol (2008) 0.76
Prevalence and clinical importance of mesenteric venous thrombosis in the Swiss Inflammatory Bowel Disease Cohort. AJR Am J Roentgenol (2014) 0.76
Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation and anti-TNF Treatment. J Pediatr Gastroenterol Nutr (2016) 0.76
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Inflamm Bowel Dis (2017) 0.75
Can fecal calprotectin or lactoferrin identify postoperative recurrence in Crohn's disease? Inflamm Bowel Dis (2010) 0.75
Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease. J Crohns Colitis (2011) 0.75
Long-Term Effiicacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. Dig Dis (2017) 0.75
Steroid use in Crohn's disease. Drugs (2014) 0.75
[Microscopic colitis: update 2014]. Rev Med Suisse (2014) 0.75
Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol (2017) 0.75
Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. Scand J Gastroenterol (2014) 0.75